Iricryn (Bimatoprost)

Bimatoprost activates prostaglandin F receptors in the eye, which increases the uveoscleral outflow of aqueous humor. The enhanced drainage reduces intra‑ocular pressure, the primary therapeutic goal in glaucoma management.

The dosing regimen for Iricryn is determined by the prescribing ophthalmologist. Typically, one drop is instilled in the affected eye(s) once daily in the evening, but the exact schedule must follow the clinician’s instructions.

Safety data for bimatoprost in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the prescriber should evaluate each case individually.

To request Iricryn, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Iricryn (bimatoprost) belongs to the prostaglandin analog class, which generally offers potent IOP reduction with once‑daily dosing. Compared with beta‑blocker or carbonic anhydrase inhibitor drops, prostaglandin analogs often achieve greater pressure lowering and have a different side‑effect profile, such as increased eyelash growth.

Store Iricryn at room temperature, below 25 °C, in the original container. Keep the bottle tightly closed, protect it from light and moisture, and discard any solution that appears discolored or contains particles.

Iricryn is applied as an ophthalmic solution. The patient should wash their hands, tilt the head back, pull down the lower eyelid, and place one drop into the conjunctival sac of the prescribed eye(s). Close the eye gently for a few seconds and avoid touching the tip of the bottle to any surface.

Serious adverse events, though rare, include severe eye inflammation (uveitis or iritis), allergic reactions with swelling or rash, sudden vision loss, and corneal edema. Patients should seek immediate medical attention if they experience intense eye pain, redness, or a rapid decline in vision.

Iricryn is contraindicated in patients with active ocular infections, known hypersensitivity to bimatoprost or any component of the formulation, and in individuals using other prostaglandin analog eye drops concurrently. Caution is also advised for pregnant or breastfeeding women and contact lens wearers.